The Winding Road to Herd ImmunityMar 18, 2021
Chief Cross-Asset Strategist Andrew Sheets talks with Biotech equity analyst Matthew Harrison on dose availability, vaccine hesitancy and the timeline for herd immunity.
As nations and the healthcare industry work to contain the spread of the coronavirus, investors search for clarity on the path ahead. Morgan Stanley analysts and economists share insights on the road ahead.
Sign up to get Morgan Stanley Ideas delivered to your inbox.
*Invalid email address
Thank You for Subscribing!
Would you like to help us improve our coverage of topics that might interest you? Tell us about yourself.